Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.
Sonoma Pharmaceuticals develops and commercializes stabilized hypochlorous acid products based on its Microcyn technology for wound care, dermatology, eye, oral and nasal care, podiatry, animal health and non-toxic disinfection. Company news commonly covers HOCl product launches, partner distribution arrangements, retail channel expansion, dermatology brand collaborations and product recognition for sensitive-skin applications.
Recurring updates also include operating and financial results, regulatory and quality initiatives, manufacturing and product-listing disclosures, international distribution activity, and board or senior leadership changes. Sonoma’s releases frequently connect its Microcyn-based formulations with consumer and professional healthcare uses, including burn relief, itch-burn-rash-pain relief, scar care and sensitive-skin dermatology products.
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported strong Q3 fiscal 2025 results with revenues increasing 14% to $3.6 million compared to the prior year. The company achieved positive cash flow from operations, maintaining $5.2 million cash at December 31, 2024.
Key developments include new partnerships with Medline Industries and WellSpring Pharmaceutical to expand U.S. sales, FDA 510(k) clearance for Microcyn technology-based hydrogel, and successful transition to EU Medical Device Regulation for four products. The company relaunched direct sales of prescription dermatology and eye care product lines.
Despite revenue growth, gross margins decreased to 36% from 47% year-over-year due to manufacturing resources allocation for European regulatory requirements. Operating expenses remained flat at $2.3 million, with a quarterly net loss of $0.9 million and EBITDA loss of $1.0 million.
Sonoma Pharmaceuticals (Nasdaq:SNOA) has successfully transitioned four of its products to meet the new European Union Medical Device Regulation (MDR) requirements, achieving Class IIb medical device classification. The products include Microdacyn60® Wound Care, Microdacyn60 Hydrogel, Epicyn® (scar gel), and Pediacyn® for atopic dermatitis.
The EU MDR, adopted in 2017 to replace the Medical Device Directive, requires compliance by December 31, 2028 for non-implantable Class IIb and lower risk devices. The classification was granted after the products met safety and performance requirements and passed conformity assessment, demonstrating their compliance with the new, more stringent European standards.
Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the relaunch of its prescription dermatology and eye care product lines in the United States. The company will now directly sell its Microcyn technology-based products, which were previously distributed through a third party. The product lineup includes prescription-strength items like Acuicyn, Epicyn, Levicyn, and Celacyn, along with over-the-counter options Lasercyn Dermal Spray and Gel. These hypochlorous acid-based products will be available from December 9, 2024, with pre-ordering options available.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has received a new FDA 510(k) clearance for its Microcyn technology-based hydrogel. The clearance includes improved biocompatibility and extended shelf life of 24 months for 50mL bottles. The product can be used professionally for managing wounds, dermal irritation, first and second degree burns, and diabetic ulcers. It's also approved for over-the-counter use on minor skin irritations, lacerations, abrasions, and minor burns, including sunburn management.
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported strong Q2 FY2025 results with significant improvements across key metrics. Revenue increased 31% to $3.6 million, driven by growth in US (14%), Europe (25%), and Latin America (79%). The company reduced its net loss by 59% to $0.6 million, while achieving positive cash flows from operations of $0.35 million. Gross profit margin improved to 38% from 36% year-over-year. The company strengthened its market position through new distribution agreements for wound care products in the US and Canada, and received FDA clearance for expanded eye care and dermatological product indications.
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its participation in MEDICA 2024, the world's largest medical trade fair, taking place in Düsseldorf, Germany from November 11-14, 2024. The event is expected to attract over 120,000 visitors from 70+ countries and 5,300+ exhibitors. Sonoma will showcase its Microcyn technology-based products for wound care, eye care, dermatological conditions, and other applications at booth F12-5 in Hall 15. The company aims to expand its distributor network and forge new partnerships through this global platform.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has expanded its partnership with a leading global healthcare distributor for marketing and distributing its wound care products in Canada. This amendment to their existing agreement, which previously covered distribution in the United States, now includes over-the-counter wound care products for sale in both countries.
The expanded partnership aims to bring Sonoma's Microcyn® technology based stabilized hypochlorous acid (HOCl) products to Canadian patients, offering improved management of acute and chronic wounds. CEO Amy Trombly highlighted the distributor's expertise and network as key factors in reaching new patients and providing greater accessibility to consumers through over-the-counter products.
Sonoma Pharmaceuticals (Nasdaq:SNOA), a global healthcare leader developing Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has announced its participation in two upcoming investor conferences:
1. Danisavage Financial Strategies Virtual 1x1 Investor Conference on October 24 at 2:00pm ET. CEO Amy Trombly and CFO Jerry Dvonch will be available for one-on-one meetings.
2. LD Micro Main Event XVII on October 29 at 1:30am PT at the Luxe Sunset Blvd Hotel in Los Angeles, CA. The presentation will be webcast live, and one-on-one meetings will be available on October 29-30, 2024.
These conferences provide opportunities for investors to learn more about Sonoma's wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has successfully regained compliance with Nasdaq's minimum bid price rule, avoiding potential delisting. The company, known for its patented Microcyn technology based on stabilized hypochlorous acid (HOCl), implemented a 1-for-20 reverse stock split on August 30, 2024. This action was taken in response to a non-compliance notice received on September 22, 2023, when SNOA's stock price fell below the required $1.00 per share minimum.
Following the reverse split, Sonoma's stock price maintained the required minimum for 10 consecutive business days, satisfying Nasdaq's compliance criteria. The company received formal confirmation from Nasdaq that it has regained compliance, and the matter is now closed. This development ensures Sonoma's continued listing on the Nasdaq Capital Market, maintaining its visibility and access to capital markets.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has received a new FDA 510(k) clearance for its Microcyn technology-based solution, expanding its over-the-counter (OTC) indications. The clearance allows for OTC management of minor skin abrasions, lacerations, and irritations on the face, eyelid, and eyelashes. This development strengthens Sonoma's position in the hypochlorous acid (HOCl) industry, particularly in eye care claims.
The company can now market its OTC dermatology products more broadly, targeting facial applications. Sonoma has also demonstrated safety, efficacy, and stability for a 2-ounce product size, opening up new packaging opportunities for consumer-friendly formats. CEO Amy Trombly emphasized that this clearance validates Sonoma's proprietary technology and expertise in HOCl, developed over two decades.